Author

Yanyan Han

The University of Texas MD Anderson Cancer CenterORCID 0009-0000-5677-9875Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Yawen WangiD· 2 shared Yonathan LissanuiD· 2 shared Hira MazhariD· 1 shared Ismail Mustafa MeraziD· 1 shared Jack A. RothiD· 1 shared Jing WangiD· 1 shared Kadir Caner AkdemiriD· 1 shared Manu M. SebastianiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Yawen WangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Medicinal ChemistryPeer-reviewedApr 25, 2025

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.

Sasikumar Kotagiri, Yawen Wang, Yanyan Han…·Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

12 citations

mouseexperimental assay

𝕏 PostBluesky

ImmunologyCancer ResearchPeer-reviewedMar 13, 2025

SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy

Yawen Wang, Ismail Mustafa Meraz, Md Qudratullah…·Yonathan Lissanu

This study shows that SMARCA4 mutations in lung cancer disrupt enhancer landscapes and innate immune gene expression, leading to immunotherapy resistance.

29 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky